Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK ‘052 Phase 1 and 2 Clinical Trials

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its partner GlaxoSmithKline (GSK) has voluntarily paused enrollment in its current clinical trials of GSK2251052 (GSK ‘052) due to a recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK ‘052 for the treatment of complicated urinary tract infections (cUTI). GSK is in the process of obtaining additional information in order to better understand the data, b

Feed Date: 
February 6, 2012